Your browser doesn't support javascript.
loading
Mucosal administration of a live attenuated recombinant COVID-19 vaccine protects nonhuman primates from SARS-CoV-2.
Tioni, Mariana F; Jordan, Robert; Pena, Angie Silva; Garg, Aditya; Wu, Danlu; Phan, Shannon I; Weiss, Christopher M; Cheng, Xing; Greenhouse, Jack; Orekov, Tatyana; Valentin, Daniel; Kar, Swagata; Pessaint, Laurent; Andersen, Hanne; Stobart, Christopher C; Bloodworth, Melissa H; Stokes Peebles, R; Liu, Yang; Xie, Xuping; Shi, Pei-Yong; Moore, Martin L; Tang, Roderick S.
Afiliación
  • Tioni MF; Meissa Vaccines Inc, Redwood City, CA, USA. mariana.tioni@meissavaccines.com.
  • Jordan R; Meissa Vaccines Inc, Redwood City, CA, USA.
  • Pena AS; Bill & Melinda Gates Foundation, Seattle, WA, USA.
  • Garg A; Meissa Vaccines Inc, Redwood City, CA, USA.
  • Wu D; Meissa Vaccines Inc, Redwood City, CA, USA.
  • Phan SI; Meissa Vaccines Inc, Redwood City, CA, USA.
  • Weiss CM; Meissa Vaccines Inc, Redwood City, CA, USA.
  • Cheng X; Meissa Vaccines Inc, Redwood City, CA, USA.
  • Greenhouse J; Meissa Vaccines Inc, Redwood City, CA, USA.
  • Orekov T; BIOQUAL Inc, Rockville, MD, USA.
  • Valentin D; BIOQUAL Inc, Rockville, MD, USA.
  • Kar S; BIOQUAL Inc, Rockville, MD, USA.
  • Pessaint L; BIOQUAL Inc, Rockville, MD, USA.
  • Andersen H; BIOQUAL Inc, Rockville, MD, USA.
  • Stobart CC; BIOQUAL Inc, Rockville, MD, USA.
  • Bloodworth MH; Department of Biological Sciences, Butler University, Indianapolis, IN, USA.
  • Stokes Peebles R; Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA.
  • Liu Y; Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA.
  • Xie X; Department of Pathology, Microbiology, and Immunology, Vanderbilt University School of Medicine, Nashville, TN, USA.
  • Shi PY; Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA.
  • Moore ML; Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA.
  • Tang RS; Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA.
NPJ Vaccines ; 7(1): 85, 2022 Jul 29.
Article en En | MEDLINE | ID: mdl-35906244
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the COVID-19 global pandemic. SARS-CoV-2 is an enveloped RNA virus that relies on its trimeric surface glycoprotein spike for entry into host cells. Here we describe the COVID-19 vaccine candidate MV-014-212, a live, attenuated, recombinant human respiratory syncytial virus expressing a chimeric SARS-CoV-2 spike as the only viral envelope protein. MV-014-212 was attenuated and immunogenic in African green monkeys (AGMs). One mucosal administration of MV-014-212 in AGMs protected against SARS-CoV-2 challenge, reducing by more than 200-fold the peak shedding of SARS-CoV-2 in the nose. MV-014-212 elicited mucosal immunoglobulin A in the nose and neutralizing antibodies in serum that exhibited cross-neutralization against virus variants of concern Alpha, Beta, and Delta. Intranasally delivered, live attenuated vaccines such as MV-014-212 entail low-cost manufacturing suitable for global deployment. MV-014-212 is currently in Phase 1 clinical trials as an intranasal COVID-19 vaccine.
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: NPJ Vaccines Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: NPJ Vaccines Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido